OSE Immunotherapeutics Presents Clinical Abstracts on Tedopi® at the ASCO 2023 Annual Meeting

OSE Immunotherapeutics SA presented a poster and a publication in abstract book featuring Tedopi®, an immunotherapy activating tumor specific T-cells, in non-small cell lung cancer and in ovarian cancer at the 2023 American Society of Clinical Oncology Annual Meeting held June 2 – 6.

Scroll to Top